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ABSTRACT
The outer membrane of Gram-negative bacteria represents a barrier for penetration of hydrophilic
compounds. Loss of porins (water-ﬁlled protein channels) contributes to antimicrobial resistance,
particularly when additional mechanisms of resistance are expressed. Many studies on the structure and
regulation of porins in Escherichia coli K-12 are available, but there is little information concerning clinical
isolates of this species. In Klebsiella pneumoniae, two major porins, OmpK35 and OmpK36, are produced,
but many extended-spectrum b-lactamase (ESBL)-producing K. pneumoniae isolates do not express
OmpK35. Loss of both OmpK35 and OmpK36 in ESBL-producing K. pneumoniae causes resistance to
cefoxitin, increased resistance to expanded-spectrum cephalosporins, and decreased susceptibility to
carbapenems, particularly ertapenem. Porin loss also decreases the susceptibility to other non-b-lactam
compounds, such as ﬂuoroquinolones, of ESBL-producing organisms.
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INTRODUCTION
The cell envelope of Gram-negative bacteria is
composed of two different membranes, separated
by the periplasm space, where the peptidoglycan
layer and b-lactamases are located [1]. The lipid
composition of the inner membrane is similar to
that of most biological membranes, including the
cytoplasmic membrane of Gram-positive organ-
isms, but the outer membrane is rather atypical,
as it is an asymmetrical bilayer of lipopolysac-
charide (outer leaﬂet) and phospholipids (inner
leaﬂet). The outer membrane contains a relatively
high proportion of saturated fatty acids and
phosphatidylethanolamine, and its permeability
to hydrophobic agents is reduced because of the
interaction of the unsaturated fatty-acid chains of
lipopolysaccharide molecules, stabilised by diva-
lent cations, which leads to a more compact
structure than if the membrane was made of only
phospholipids. This reduced permeability pre-
vents the penetration of multiple toxic com-
pounds, helping the cell to survive in adverse
environments [1].
Despite its relative impermeability, the outer
membrane has to allow different hydrophilic
compounds to enter (nutrients) or to leave (toxic
waste) the cell, and outer membrane proteins
(OMPs) are critical in this function [2]. The outer
membrane contains lipoproteins (anchored to the
phospholipid leaﬂet) and integral proteins. The
latter are usually made of anti-parallel b-strands
with a barrel-like structure functioning as trans-
membrane hydrophilic pores [3]. It is usual to
distinguish, from a functional point of view,
between non-speciﬁc and speciﬁc pores. It has
been proposed that non-speciﬁc pores should be
called porins, but in the literature this term is also
often used for channels allowing penetration of
speciﬁc substrates.
Most studies on porins have been done in
Enterobacteriaceae, particularly Escherichia coli
(and especially the laboratory strain E. coli K-12),
Klebsiella pneumoniae and Enterobacter spp. Infor-
mation is also available for Pseudomonas aeruginosa
and, to a lesser extent, Acinetobacter baumannii.
Limited information has been reported for other
organisms, e.g., Vibrio, Neisseria, Helicobacter or
Campylobacter. Several reviews are available on
the structure, biogenesis and regulation of these
proteins [1,3–5].
There are two major non-speciﬁc porins,
OmpF and OmpC, in E. coli K-12. Both are
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trimeric proteins. The functional pore of OmpF
(with a diameter of about 12 A˚ and a preference
for cations) is slightly larger than that of OmpC
[6]. The porin b-strands (usually 16 per mono-
mer) are tilted (30–60) in relation to the vertical
axis of the pore, and transmembrane segments
are connected with short turns (at the periplas-
mic space) or rather long loops (at the external
cell surface). An important structural feature of
OmpF is that loop 3 (33 residues long) folds into
the pore and narrows it [1]. Two major porins,
OmpK35 (a homologue of OmpF) [7,8] and
OmpK36 (a homologue of OmpC) [9], have also
been described in K. pneumoniae. The OmpK36
crystal structure has been resolved, indicating
that it is rather similar to OmpF from E. coli [10].
In Salmonella enterica (with the notable exception
of serovar Typhi), there is an additional porin,
OmpD, with properties similar to those of OmpF
and OmpC [11]. Enterobacter also contains genes
analogous to ompF and ompC, and preliminary
studies indicate that it also expresses OmpD [12].
Proteus spp., Providencia spp. and Morganella
morganii seem to produce only a single major
non-speciﬁc porin, but very few studies have yet
been done on the porins of these three genera
[13].
E. coli also express the OmpA protein, a homo-
logue of the major porin of P. aeruginosa OprF [1].
OmpA-like proteins are also found in other
enterobacteria; in K. pneumoniae, the correspond-
ing protein is OmpK34. OmpA is monomeric and
contains some helical structures. It allows the
penetration of solutes, but it has a very low
efﬁciency, about 100 times lower than the non-
speciﬁc trimeric porins [1].
Speciﬁc pores of enterobacteria, such as LamB
(which allows entry of maltose derivatives, and
acts as a receptor for phage lambda) and PhoE
(speciﬁc for phosphate), have a general structure
rather similar to that of the non-speciﬁc porins,
but the actual residues lining the interior of the
pore are sufﬁciently different to give a different
functional speciﬁcity.
In addition to the major porins, minor proteins
with a porin structure have been described in
several enterobacteria; these include NmpC and
OmpN of E. coli, OmpK37 of K. pneumoniae and
OmpS2 of Salmonella typhi [14]. They are quies-
cent porins, and expression is not detected in
the outer membrane of strains grown under
standard laboratory conditions, indicating that
the corresponding genes are strongly down-
regulated.
Multiple studies have concerned porins of
P. aeruginosa, in particular the speciﬁc porin
OprD, which is involved in basic amino-acid
transport, and is important for carbapenem pen-
etration [15]. More recently, several studies on
porins of A. baumannii have been reported [16].
There is, however, very little information on the
relevance of porin alterations as a mechanism
complementing extended-spectrum b-lactamase
(ESBL)-mediated resistance in these organisms.
Moreover, ESBLs are much less prevalent than in
enterobacteria, and for these reasons, non-fer-
menting organisms will not be covered further in
this review.
PORIN LOSS AND RESISTANCE TO
ANTIMICROBIAL AGENTS:
GENERAL ASPECTS
The loss of non-speciﬁc porins has been related
to increased resistance to hydrophilic antimicro-
bial agents, with studies in this area being
focused on b-lactams and ﬂuoroquinolones.
However, the demonstration of the actual role
of porins in antimicrobial resistance is complex
and should not rely simply on the observa-
tion of (presumed) porin bands in SDS-PAGE
gels.
Porins are trimeric proteins that are highly
stable to detergents and salts (due to their high
b-sheet content) but are heat-modiﬁable; conse-
quently, if an OMP in an unboiled sample runs
with an apparent molecular mass of approxi-
mately three times that of the monomer in a
boiled sample, it is probably a porin.
The outer membrane proﬁles depend on the
conditions (e.g., osmolarity, temperature) in
which the organism was grown. It is generally
accepted that OmpF and OmpK35 are expressed
in low-osmolarity media, while their production
is repressed in high-osmolarity media, where
OmpC production is favoured [5,17,18]. The
pattern of proteins also varies with the gel
composition. Optimal resolution (separation) of
the K. pneumoniae porins is obtained, depending
on the strain, on resolving gels containing 11%
acrylamide and either 0.21%, 0.35% or 0.55% bis-
acrylamide [18]. Adding urea (usually in the
range of 4–8 M) to the resolving gel of SDS-PAGE
systems helps in deﬁning porin bands of E. coli
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(but causes blurred images when studying
K. pneumoniae porins).
Several functional assays can be used in deﬁn-
ing a role for porin loss in resistance. In the case of
b-lactams, permeability rates may be indirectly
inferred spectrophotometrically from the ability
of periplasmic b-lactamase to hydrolyse the
assayed antimicrobial agent in comparison with
hydrolysis by free, puriﬁed enzyme [6,19]. This
indirect approach has the limitation that, in most
cases, only a single, or just a few, compound(s)
are tested, and results for other agents have
simply been assumed to be related.
In the liposome swelling assay, liposomes are
reconstituted with puriﬁed porins, and the uptake
of sugars with different molecular sizes is tested
[8,14]. For a given porin, the penetration of sugars
decreases as the size of the compound increases,
allowing an indirect estimation of the functional
diameter of the pore.
Another, more direct, approach to prove the
role of a lost OMP in antimicrobial resistance is to
demonstrate a decrease in the MIC of antimicro-
bial agents against an organism when it re-
expresses the lost OMP following introduction
of an engineered plasmid encoding the corre-
sponding gene [20].
ALTERED PERMEABILITY AND
RESISTANCE IN ESBL-PRODUCING
K. PNEUMONIAE
Multiple studies indicate that porin loss from
K. pneumoniae strains lacking other mechanisms
of resistance does not cause clinically relevant
resistance. MICs of b-lactams, ﬂuoroquinolones,
aminoglycosides, tetracycline and chlorampheni-
col against mutants deﬁcient in antigen O, cap-
sule or either OmpK35 or OmpK36 derived from
an ampicillin-susceptible K. pneumoniae strain
were within one dilution of those against the
parental strain [21]. For the mutant simulta-
neously lacking the two porins, and expressing
increased amounts of b-lactamase, there were no
changes in the MICs of ﬂuoroquinolones or
aminoglycosides, and the MICs of ampicillin,
cefoxitin, cefotaxime and ceftazidime increased
four to >256 times [21].
ESBL-producing K. pneumoniae strains more
often express only OmpK36 than do strains
lacking these enzymes, which usually contain
both OmpK35 and OmpK36 [18,22]. The absence
of OmpK35 may be one of the factors contributing
to antimicrobial resistance in ESBL-producing
K. pneumoniae and may favour the selection of
additional mechanisms of resistance. More gen-
erally, as OmpK35 is not normally expressed in
high-osmolarity media, it is possible that its
expression is repressed in vivo. This may be of
therapeutic importance.
Cefoxitin and other cephamycins are not good
substrates for ESBLs and, in theory, might repre-
sent an option for treating infections caused by
ESBL-producing organisms. However, several
studies have demonstrated that cefoxitin is read-
ily able to select resistant K. pneumoniae mutants
that are deﬁcient in the two major porins, both
in vivo and in vitro [20]. There is no clear proof
that this observation is valid for other cephamy-
cins, e.g., cefotetan. In a study on 12 clinical
isolates of K. pneumoniae producing ESBLs and
lacking both OmpK35 and OmpK36, the MICs of
cefoxitin were ‡32 mg ⁄L for all isolates, but those
of cefotetan were £16 mg ⁄L for 11 isolates. This is
in contrast to 19 K. pneumoniae isolates with
plasmid-mediated AmpC-type b-lactamases
(pAmpC), where MICs of both cefoxitin and
cefotetan were ‡32 mg ⁄L for 19 and 15 isolates,
respectively.
As shown in Table 1, MICs of cefoxitin, but also
of oxyimino-cephalosporins such as cefotaxime,
are increased for porin-deﬁcient mutants with
ESBLs. Cloning and expression of a plasmid-
borne ompK36 gene in strains lacking both
OmpK35 and OmpK36 (Table 2) demonstrated
that porin loss was directly involved in resistance
to cefoxitin and oxyimino-cephalosporins in both
organisms [20,23]. In subsequent studies using the
same approach, the role of OmpK35 was also
evaluated [8]. Expression of this protein in an
isolate lacking both OmpK35 and OmpK36
Table 1. MICs (mg ⁄L) of b-lactams for two pairs (LB3-LB4
andCSUB10S-CSUB10R) of extended-spectrumb-lactamase
(ESBL)-producing Klebsiella pneumoniae strains of clinical
origin, producing porins or nota
Strain ESBL OmpK36 FOX CAZ CTX IMP MPM
LB3 SHV-5 + 4 >256 4 0.25 NT
LB4 SHV-5 ) 128 >256 64 0.25 NT
CSUB10S SHV-2 + 2 >256 4 0.125 0.03
CSUB10R SHV-2 ) 128 >256 512 0.5 4
aAll four organisms lack porin OmpK35.
NT, not tested; FOX, cefoxitin; CAZ, ceftazidime; CTX,
celotaxime; IMP, irnipenem; MPM, menopenem
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caused a reduction of the MICs of most
expanded-spectrum b-lactams.The greatest reduc-
tions were noted for cephamycins, oxyimino-
cephalosporins, zwitterionic cephalosporins and
meropenem. A signiﬁcant reduction was also
obtained for imipenem. These reductions were
four to eight times (cefepime, cefotetan, cefotax-
ime, and cefpirome), or 128 times (ceftazidime)
higher than those observed when OmpK36 was
expressed in the same organism. The level of
resistance further increased when a high inocu-
lum (107 CFU ⁄mL) was used, and this may be
clinically relevant when the number of bacteria at
the site of infection is high. Expression of
OmpK35 in a K. pneumoniae strain already pro-
ducing OmpK36 (resulting in an organism with
both major porins) caused decreases in the MICs
of b-lactams identical to, or one dilution step
greater than, those for the derivative expressing
only OmpK35 [8]. This suggests that, at least in
K. pneumoniae, expression of just one of the two
major porins may be sufﬁcient for b-lactam
penetration, and that resistance to cefoxitin and
increased resistance to other compounds requires
loss of both OmpK35 and OmpK36 (Table 2).
Carbapenems are usually active against ESBL-
producing strains, including those that lack major
porins. This is related to the high stability of these
molecules in the presence of ESBLs; in addition,
imipenem is a zwitterion and is small, which
facilitates diffusion through the outer membrane.
Resistance (as deﬁned by EUCAST; http://www.
srga.org/eucastwt/MICTAB/MICcarbapenems.
html) to imipenem (MIC 8 mg ⁄L) and to merope-
nem (MIC 16 mg ⁄L) was described in a clinical
isolate of K. pneumoniae producing SHV-2, lacking
OmpK35, and producing reduced amounts of
OmpK36 [24]. Using derivatives of a strain deﬁ-
cient in both OmpK35 and Ompk36 and produc-
ing different b-lactamases, resistance to imipenem
and meropenem was observed when class A or D
carbapenemases or some pAmpC types were
produced [25,26]. For the construct expressing
SHV-2, the MIC of imipenem was 16 mg ⁄L at an
inoculum of 107 CFU ⁄mL [25]. Resistance to
ertapenem was also obtained when carbapene-
mases (practically all tested), pAmpC, OXA-32
and some TEM-type ESBLs were expressed; the
MICs of this compound ranged from 4 to 16 mg ⁄L
when SHV-type, CTX-M-5 or -14 and other TEM
types were expressed [26]. Ertapenem resistance
has been observed in two isolates of K. pneumoniae
from a patient treated with ertapenem [27]. The
isolates lacked porins and produced an ESBL of
the CTX-M-1 group. Two other clonally related
isolates, producing the same ESBL and expressing
porins, were susceptible to ertapenem. The porin-
deﬁcient strains showed decreased activity of
meropenem (MIC 4–8 mg ⁄L), but the activity of
imipenem was not much affected (MIC 0.5–
1 mg ⁄L). In another independent study, carbape-
nem resistance was documented in two isolates of
K. pneumoniae deﬁcient in both OmpK35 and
OmpK36 and producing CTX-M-1, cultured from
patients treated with imipenem or meropenem
[28]. The clinical implications of these data may be
of great concern; while ertapenem may be more
severely affected than other carbapenems, favour-
ing the use of imipenem or meropenem may
translate into additional selective pressure for
multiresistant non-fermenters or into the expan-
sion of carbapenemase-producing enterobacteria.
Re-expression of the OmpK35 gene and, to a
lesser extent, of theOmpK36 gene in K. pneumoniae
deﬁcient in both porins also caused a reduction in
the MICs of ciproﬂoxacin, chloramphenicol, and
tetracycline [8], although this reduction was min-
imal or absent for compounds to which the
organism was already susceptible (clinaﬂoxacin,
amikacin, and gentamicin). This particular strain
contained a Ser83Phe change in the A subunit
of DNA gyrase and showed active efﬂux of
Table 2. MICs (mg ⁄L) of b-lactams
for clinical isolates and laboratory
mutants of Klebsiella pneumoniae
strains expressing porins OmpK35
and ⁄ or OmpK36
Strain Porin FOX CTX IMP MPM
CSUB10S OmpK36 2 4 0.125 0.03
CSUB10R Nonea 128 512 0.5 4
CSUB10R pSHA25 OmpK36 2 4 0.25 0.03
CSUB10R pSHA16 OmpK35 1 0.5 0.125 0.03
CSUB10S pSHA16 OmpK35, OmpK36 1 1 0.125 0.03
CSUB10R pQ3 OmpK37 (low-level) 128 512 0.5 1
CSUB10R pQ7 OmpK37 (high-level) 64 512 0.25 0.125
aNone: absence of both OmpK35 and OmpK36.
FOX, cefoxitin; CTX, celotaxime; IMP, irnipenem; MPM, menopenem
Martı´nez-Martı´nez ESBL and the permeability barrier 85
 2008 The Author
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14 (Suppl. 1), 82–89
ﬂuoroquinolones. As both mechanisms affected
ciproﬂoxacin more efﬁciently than clinaﬂoxacin,
the difference inMIC between the two compounds
decreases, again suggesting that loss of porins has
a greater effect when another mechanism of
resistance is also present. Porin-deﬁcient ESBL-
producing K. pneumoniae strains more often
express active efﬂux of quinolones than those
expressing porins, and active efﬂux is more
common among ESBL-positive strains than
among ESBL-negative strains [22]. It may be
possible that efﬂux works better in porin-deﬁcient
strains. Organisms producing both ESBL and the
Qnr proteins involved in quinolone resistance
have increasingly been reported in recent years
[29].
These studies on K. pneumoniae were extended
to a collection of 50 clinical isolates producing at
least one porin and 15 isolates lacking both
OmpK35 and OmpK36. It was shown again that
loss of porins is critical for cefoxitin resistance,
and that resistance to other expanded-spectrum
b-lactam antibiotics was increased in porin-deﬁ-
cient organisms. In terms of MIC50 and MIC90,
meropenem was more active than imipenem
against both porin-expressing and porin-deﬁcient
strains, but MIC ranges of meropenem for the
latter were broader, indicating that, for a subset of
strains deﬁcient in porins, the activity of merope-
nem is more affected than that of imipenem [30].
The mechanisms controlling porin loss in
K. pneumoniae are still poorly understood. This
organism contains a homologue of marA (see
below for the regulatory effect of this gene in
E. coli) [31]. Independently, it has been reported
that direct interruption of the ompK36 gene by
insertion sequences and, less frequently, point
mutations or deletions explains the loss of the
OmpK36 porin in both laboratory and clinical
strains. Similar mechanisms may control loss of
OmpK35 [32].
The minor OmpK37 porin allows the penetra-
tion of carbapenems (but not other b-lactams) into
the cell. Its predicted secondary structure has an
insertion of one bulky residue (Tyr118) in loop 3,
presumably narrowing the pore [14]. When it is
overexpressed in isolates deﬁcient in both
OmpK35 and OmpK35, MICs of both imipenem
and meropenem decrease, but as the amount of
this protein in the outer-membrane is negligible
when it is expressed from its natural promoter, it
is difﬁcult to have a precise idea about the
importance of its down-regulation in carbapenem
resistance [14].
The importance of other speciﬁc pores in the
resistance of K. pneumoniae to antimicrobial agents
has been little explored. It is not clear whether
LamB expression (observed in Mueller–Hinton
media) directly facilitates the penetration of
hydrophilic compounds, and whether its loss
may be involved in increased resistance. Com-
parison of clonally related carbapenem-suscepti-
ble and carbapenem-resistant clinical isolates of
K. pneumoniae lacking both OmpK35 and
OmpK36 showed down-regulation of ompK37,
phoB and phoE in the latter [33]. Expression of
the native phoE gene under the control of the
heterologous lacZ promoter reversed carbapenem
resistance, whereas this was not the case with the
native promoter [33]. It is possible that expression
of PhoE is responsible for carbapenem suscepti-
bility in the porin-deﬁcient background (because
of compensation for the loss of major non-speciﬁc
porins), and that down-regulation of phoE was
involved in the carbapenem resistance.
ALTERED PERMEABILITY AND
RESISTANCE IN E . COLI PRODUCING
ESBL
Multiple studies on the structure, function and
regulation of porins in E. coli K-12 have been
reported. OmpF and OmpC are the major porins
of this organism. They are under the control of
several systems, including the two-component
system ompR–envZ [5] and the sox and mar
operons. The latter interferes with the expression
of ompF by the RNA antisense micF and, addi-
tionally, activates the acrAB genes involved in
active efﬂux of antimicrobial agents [34].
Despite these data, and in contrast to what is
known about ESBL-producing K. pneumoniae,
there is scarce information concerning the true
number and nature of porins expressed by clinical
isolates of E. coli, and on the relationship of porin
expression, if any, to antimicrobial resistance,
particularly for ESBL-producing clinical isolates.
Preliminary reports indicated that loss of both
OmpF and OmpC causes resistance to b-lactams
when they are substrates for an efﬁcient b-lac-
tamase [35,36]. Loss of OmpF alone in mutants
expressing TEM-3 or -9 caused moderate changes
(two- to four-fold increases) in MICs, as compared
with the equivalent mutant expressing OmpF.
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Remarkably, the MICs of both imipenem and
meropenem were slightly higher (still within the
range of clinical susceptibility) for the strain
lacking OmpF [36].
Electrophoretic analysis of porins from 50
E. coli isolates producing ESBLs grown in low-
and high-osmolarity media indicated that only
four (8%) of them presented a proﬁle similar to
that of E. coli K-12. Four other major proﬁles were
noted among this collection of organisms, char-
acterised by different models of expression of
OMP with mobilities similar to those of OmpF
and OmpC of the K12 strain. There were no clear
correlations between porin proﬁles and resistance
to cefoxitin or to expanded-spectrum cephalos-
porins.
ENTEROBACTER AND OTHER
ENTEROBACTERIACEAE
There are several reports on the association of
porin loss and increased resistance to antimicro-
bial agents in other species, including S. enterica,
Enterobacter spp., and Serratia spp. [19,37,38].
Although these descriptions do not speciﬁcally
refer to ESBL-producing organisms, it seems
likely that the basic observations outlined above
for K. pneumoniae and E. coli are also valid for
these related bacteria. Nevertheless, some pecu-
liarities are expected to be discovered in these
genera and, in fact, some original observations
have already been made.
Omp35 and Omp36 have been characterised in
detail in Enterobacter. Omp35 (like OmpK35 of
K. pneumoniae) contains several negatively
charged amino-acids in the L3 region of the pore,
and these are of critical relevance for higher
permeability, in comparison with Omp36 [12].
Reduced permeability for antimicrobial agents
has been documented in an Enterobacter aerogenes
porin with a structural change in loop 3 [39]. It is
possible that similar changes occur in K. pneumo-
niae strains with reduced susceptibility to cefox-
itin but still expressing porins in their outer
membrane (unpublished data).
Studies in Enterobacter (and other enterobacte-
ria) have shown that, independently of porin
changes caused by environmental alterations
(e.g., in pH, osmolarity, O2 concentration), the
function of porins may be altered by polyamines
because of the interaction between their amino
groups and amino-acids lining the internal sur-
face of the channel. This has been demonstrated
for OmpF of Enterobacter cloacae, where spermine
causes decreased penetration of cefepime and
norﬂoxacin [40]. OmpX has been shown to be
related to decreased expressions of major porins
in Enterobacter [41].
FUTURE PROSPECTS
Porin loss may increase the level of resistance to
b-lactams inESBL-producingorganisms, especially
if there is simultaneous expression of other
b-lactamases. This may result in very complex
phenotypes that are difﬁcult to recognise in the
clinical laboratory, sometimes masking the typical
ESBL phenotype. New testing approaches are
required and should eventually be incorporated
into the expert systems of automatic susceptibility
testingdevices.Available information suggests that
porin loss may contribute to resistance in K. pneu-
moniae differently than in other Enterobacteriaceae,
including E. coli. Thus, it may be unwise to extrap-
olate from observations in one organism and,
similarly, data obtained with laboratory strains do
not always apply to clinical isolates.
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